{
  "actions": [
    {
      "acted_at": "2018-07-26", 
      "action_code": "Intro-H", 
      "references": [], 
      "text": "Introduced in House", 
      "type": "action"
    }, 
    {
      "acted_at": "2018-07-26", 
      "action_code": "H11100", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2018-07-27", 
      "action_code": "", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr6576-115", 
  "bill_type": "hr", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }
  ], 
  "congress": "115", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2018-07-26", 
  "number": "6576", 
  "official_title": "To require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "s2157-115", 
      "identified_by": "CRS", 
      "reason": "identical", 
      "type": "bill"
    }
  ], 
  "short_title": "Drug-Price Transparency in Communications Act", 
  "sponsor": {
    "bioguide_id": "S001145", 
    "district": "9", 
    "name": "Schakowsky, Janice D.", 
    "state": "IL", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2018-07-26", 
  "subjects": [
    "Health"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced in House", 
    "date": "2018-07-26T04:00:00Z", 
    "text": "Drug-Price Transparency in Communications Act\n\nThis bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.\n\nThe bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.", 
      "type": "official"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Drug-Price Transparency in Communications Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Drug-Price Transparency in Communications Act", 
      "type": "short"
    }, 
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Drug-Price Transparency in Communications Act", 
      "type": "display"
    }
  ], 
  "updated_at": "2019-11-15T21:20:57Z", 
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/115/hr/BILLSTATUS-115hr6576.xml"
}